Home » Stocks » CNMD

CONMED Corporation (CNMD)

Stock Price: $123.18 USD -3.20 (-2.53%)
Updated Feb 25, 2021 1:56 PM EST - Market open
Market Cap 3.65B
Revenue (ttm) 862.46M
Net Income (ttm) 9.52M
Shares Out 28.60M
EPS (ttm) 0.32
PE Ratio 384.94
Forward PE n/a
Dividend $0.80
Dividend Yield 0.65%
Trading Day February 25
Last Price $123.18
Previous Close $126.38
Change ($) -3.20
Change (%) -2.53%
Day's Open 125.61
Day's Range 122.18 - 126.79
Day's Volume 93,531
52-Week Range 37.39 - 129.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vi...

Zacks Investment Research - 4 weeks ago

Despite weak segmental performance in fourth quarter, CONMED (CNMD) showed strength and resilience in amid a tough operating environment.

Seeking Alpha - 4 weeks ago

CONMED Corporation (CNMD) CEO Curt Hartman on Q4 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 weeks ago

Conmed (CNMD) delivered earnings and revenue surprises of 7.69% and -3.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 4 weeks ago

Shares of Conmed (NYSE:CNMD) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 6.67% over the past year to $0.84, which be...

Business Wire - 4 weeks ago

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter ended December 31, 2020. Fourth Quarter 2020 Highlights Sales of $252.8 m...

Business Wire - 1 month ago

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the fourth quarter and full year 2020 after the market close on Wednesda...

Business Wire - 1 month ago

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President & Chief Executive Officer, and Todd W. Garner, Executive Vice ...

Zacks Investment Research - 1 month ago

MCK vs. CNMD: Which Stock Is the Better Value Option?

Other stocks mentioned: MCK
Zacks Investment Research - 3 months ago

Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.

Business Wire - 3 months ago

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, President, Chief Executive Officer and Chair of the Board, and Todd W. Garner, Executive Vic...

Business Wire - 3 months ago

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on January 5, 2021 ...

Business Wire - 3 months ago

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its presentation time at the Jefferies Virtual London Healthcare Conference has been changed to 11:25 a.m. ET...

Business Wire - 3 months ago

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the Jefferies Virtual L...

Business Wire - 3 months ago

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, President, Chief Executive Officer and Chair of the Board, and Todd W. Garner, Executive Vic...

Zacks Investment Research - 3 months ago

CONMED's (CNMD) General Surgery unit witnessed revenue growth in Q3

Seeking Alpha - 3 months ago

CONMED Corporation's (CNMD) CEO Curt Hartman on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Conmed (CNMD) delivered earnings and revenue surprises of 252.00% and 16.07%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 months ago

Shares of Conmed (NYSE:CNMD) decreased 2.4% in after-market trading after the company reported Q3 results. Quarterly Results

Business Wire - 3 months ago

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Highlights Sales of $237.8 mi...

Zacks Investment Research - 4 months ago

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter of 2020 after the market close on Wednesday, October 2...

Zacks Investment Research - 5 months ago

Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.

Business Wire - 5 months ago

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R.

Zacks Investment Research - 6 months ago

PDCO vs. CNMD: Which Stock Is the Better Value Option?

Other stocks mentioned: PDCO
Business Wire - 6 months ago

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2020 ...

Zacks Investment Research - 6 months ago

CONMED's (CNMD) core units - General Surgery and Orthopedic Surgery - witnessed revenue decline in Q2.

Seeking Alpha - 6 months ago

CONMED Corporation's (CNMD) CEO Curt Hartman on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Conmed (CNMD) delivered earnings and revenue surprises of 93.14% and 22.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 6 months ago

Shares of Conmed (NYSE:CNMD) moved higher by 4.42% in after-market trading after the company reported Q2 results.

Business Wire - 6 months ago

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2020.

Benzinga - 6 months ago

On Wednesday, July 29, Conmed (NYSE: CNMD) will report its last quarter's earnings.

Zacks Investment Research - 6 months ago

CONMED (CNMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 7 months ago

Conmed (CNMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 7 months ago

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 7 months ago

PDCO vs. CNMD: Which Stock Is the Better Value Option?

Other stocks mentioned: PDCO
Zacks Investment Research - 8 months ago

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 8 months ago

CONMED (CNMD) continues to benefit from broad product portfolio and persistent focus on R&D. However, forex remains a woe.

Zacks Investment Research - 9 months ago

CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.

Seeking Alpha - 9 months ago

CONMED Corporation (CNMD) CEO Curt Hartman on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Conmed (CNMD) delivered earnings and revenue surprises of 15.91% and 2.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

MMSI vs. CNMD: Which Stock Is the Better Value Option?

Other stocks mentioned: MMSI
Zacks Investment Research - 11 months ago

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.

Zacks Investment Research - 11 months ago

The coronavirus pandemic likely to disrupt the first-quarter performances of players in the MedTech space.

Other stocks mentioned: BSX, COO, ECL
Market Watch - 11 months ago

Medical technology company Conmed Corp. CNMD, -12.37% issued a revenue warning for the first quarter on Tuesday to reflect the impact on its business of the coronavirus that causes COVID-19.

Zacks Investment Research - 11 months ago

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

XRAY vs. CNMD: Which Stock Is the Better Value Option?

Other stocks mentioned: XRAY
Zacks Investment Research - 1 year ago

XRAY vs. CNMD: Which Stock Is the Better Value Option?

Other stocks mentioned: XRAY
Zacks Investment Research - 1 year ago

CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.

About CNMD

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, p... [Read more...]

Industry
Medical Devices
IPO Date
Jul 23, 1987
CEO
Curt Hartman
Employees
3,400
Stock Exchange
NYSE
Ticker Symbol
CNMD
Full Company Profile

Financial Performance

In 2020, CNMD's revenue was $862.46 million, a decrease of -9.70% compared to the previous year's $955.10 million. Earnings were $9.52 million, a decrease of -66.75%.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CNMD stock is "Buy." The 12-month stock price forecast is 129.00, which is an increase of 4.72% from the latest price.

Price Target
$129.00
(4.72% upside)
Analyst Consensus: Buy